TROMBEX 75mg x 30 tabl
Secondary prevention of atherothrombotic events Clopidogrel is indicated in: • adult patients with a history of myocardial infarction (from a few days to 35 days), ischemic stroke (from the 7th day to the 6th month) or established peripheral arterial disease. • adult patients with acute coronary syndrome: - Acute coronary syndrome without ST-segment elevation (unstable angina or non-Q-wave myocardial infarction), including patients who have undergone stenting after percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - Acute myocardial infarction with ST-segment elevation, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients who have undergone stenting) or medically treated patients suitable for thrombolytic/fibrinolytic therapy. In patients with a transient ischemic attack (TIA) at moderate to high risk or a mild ischemic stroke (IS) Clopidogrel in combination with ASA is indicated in: - Adult patients with a moderate to high risk TIA (ABCD2 score ≥4) or mild IS (NIHSS ≤3) within 24 hours of the TIA or IS event. Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events who are not suitable for treatment with a vitamin K antagonist (VKA) and who are at low risk of bleeding, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. For further information, see section 5.1. Clopidogrel (as hydrogen sulphate) 75mg
